It also provides vital insights into stem cell technologies and
therapies that have already proven to be successful and analyzes those which have potential future value. The
regulatory climate and proprietary landscape are discussed, enabling you to formulate and optimize your stem cell
strategies and position yourself for growth in this emerging market. Use this latest report to recognize areas
poised for growth in the market for tissue repair and regeneration, identify potential alliance partners and plan a
long-term growth strategy to secure your leading position in this market.


Scope of this report

• Growth forecasts for stem cell market sub-sectors to 2010.
  

• An examination of proprietary technologies and company strategies shaping the market for adult,
  embryonic and fetal stem cell products.
  

• Assessment of the therapeutic potential of human stem cells for tissue repair and regeneration.
  

• Analysis of global regulatory issues which are dictating where and how embryonic stem cell research is
  being done.
  

Key reasons to read this report

• The market for stem cell products and services (including cytokines) is forecast to grow almost three-
  fold from $24.6 billion in 2005 to $68.9 billion in 2010.
  

• During the years 1980-2005, over 2,000 US patents claiming stem cell technologies and applications
  relevant to healthcare were published; the annual publication rate accelerated sharply in 2002.
  

• The majority of adult stem cell R&D is conducted in the US, while most embryonic stem cell research is
  conducted outside the US due to a restrictive legislative environment.
  

• In 2005, the first commercial product containing adult stem cells was launched in the US - Osiris
  Therapeutics Osteocel.